Analyst firms · H.C. Wainwright · VRCA
H.C. Wainwright VRCA price target and rating history
Verrica Pharmaceuticals Inc. (VRCA) · Health Care
H.C. Wainwright rates Verrica Pharmaceuticals Inc. (VRCA) Buy with a $12 price target, as of its latest action on May 26, 2026. It has published 3 rating actions on VRCA since September 2021, including 0 upgrades and 1 downgrade.
- Current rating
- Buy
- Price target
- $12
- Median target, all firms
- Too few
- Actions on VRCA
- 3
H.C. Wainwright price target on VRCA
Every H.C. Wainwright rating on VRCA
- May 26, 2026
- Nov 6, 2024
- Sep 22, 2021
How other firms rate VRCA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Lake Street | Buy | $9 | Aug 27, 2026 |
| H.C. Wainwright | Buy | $12 | May 26, 2026 |
Questions about H.C. Wainwright and VRCA
- What is H.C. Wainwright's price target for VRCA?
- H.C. Wainwright's latest stated price target for Verrica Pharmaceuticals Inc. (VRCA) is $12, from its action on May 26, 2026.
- What is H.C. Wainwright's rating on VRCA?
- H.C. Wainwright rates VRCA Buy, a bullish rating, as of May 26, 2026.
- When did H.C. Wainwright last change its view on VRCA?
- On May 26, 2026, H.C. Wainwright resumes coverage at Buy, price target $12.
More VRCA rating histories
All H.C. Wainwright ratingsVRCA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.